Welcome to our dedicated page for Alkermes plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc stock.
Alkermes Inc. plc (NASDAQ: ALKS) is a global biopharmaceutical company dedicated to developing innovative medicines for treating central nervous system (CNS) diseases. Headquartered in Dublin, Ireland, Alkermes has a significant presence in the United States with a research and development center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The company’s mission is to leverage its proprietary technologies to create and commercialize pharmaceutical products that address unmet medical needs in conditions such as schizophrenia, depression, addiction, and multiple sclerosis.
Alkermes’ diversified product portfolio includes notable medications like LYBALVI®, ARISTADA®, and VIVITROL®. These products are pivotal in the treatment of mental health disorders and substance abuse, demonstrating the company's commitment to enhancing patient outcomes. LYBALVI®, a combination of olanzapine and samidorphan, is used for treating schizophrenia and bipolar I disorder. ARISTADA® is an extended-release injectable suspension for schizophrenia, and VIVITROL® is used for alcohol and opioid dependence.
The company's robust clinical pipeline features breakthrough candidates such as ALKS 2680, an investigational orexin 2 receptor agonist targeting narcolepsy. Recent study results announced in early 2024 have shown promising improvements in wakefulness for patients with narcolepsy type 2 and idiopathic hypersomnia, validating the potential of ALKS 2680 to address critical gaps in treatment.
Alkermes has also engaged in significant corporate developments, including the sale of its Athlone, Ireland facility to Novo Nordisk, aimed at increasing operational efficiency. Financially, the company reported total revenues of $1.66 billion for 2023, with a net income of $356 million, emphasizing strong growth and profitability. The company's strategic focus on neuroscience and operational efficiency is expected to drive sustained profitability and innovation in treating CNS disorders.
For more detailed information about Alkermes’ products, clinical trials, and corporate strategies, you can visit their official website at www.alkermes.com.
Alkermes plc (Nasdaq: ALKS) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 10:25 a.m. ET and the Piper Sandler 36th Annual Healthcare Conference on December 4 at 4:00 p.m. ET.
The presentations will be accessible via live webcasts on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes plc (Nasdaq: ALKS) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel Healthcare Conference on November 18 at 8:35 a.m. ET and the Jefferies London Healthcare Conference on November 19 at 8:00 a.m. ET. Live webcasts will be available on Alkermes' website under the Investors tab and archived for 14 days.
Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.
Alkermes announced presentations at two key scientific conferences, showcasing research on LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil), and ALKS 2680. At the 37th Annual Psych Congress and the 2024 Neuroscience Education Institute Congress, Alkermes presented 12 posters, including a study on healthcare resource utilization in patients with schizophrenia and bipolar I disorder after LYBALVI initiation. The study revealed significant reductions in inpatient admissions and emergency department visits. Limitations include potential data omissions and coding errors. Additionally, safety and efficacy data from a phase 1b study of ALKS 2680 in narcolepsy were presented.
Alkermes (ALKS) reported strong Q3 2024 financial results with total revenues of $378.1 million. Net sales of proprietary products grew 18% year-over-year, with GAAP net income from continuing operations at $92.8 million. Key product performance includes LYBALVI revenues of $74.7 million (47% growth), ARISTADA at $84.7 million, and VIVITROL at $113.7 million (14% growth). The company maintains its 2024 financial guidance and continues to advance its pipeline, particularly ALKS 2680, its orexin 2 receptor agonist for narcolepsy treatment. During Q3, Alkermes repurchased approximately 4.4 million shares for $115.6 million, with $200 million remaining in the program.
Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast presentation on Thursday, October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results. The event will be accessible via the Investors section of Alkermes' website, with a webcast player and accompanying slides available. Participants can join the conference call by dialing +1 877 407 2988 (U.S. callers) or +1 201 389 0923 (international callers).
Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia.
Alkermes plc (Nasdaq: ALKS) has announced an investor event scheduled for October 9, 2024, at 10:00 a.m. EDT in Waltham, Mass. The event will focus on reviewing the company's orexin portfolio and development strategy. It will feature presentations by Alkermes' Research & Development team, followed by a clinician and thought leader panel discussion and a Q&A session.
The event will be accessible virtually via webcast, with registration available on the Investors section of Alkermes' website. A replay will be archived for 30 days following the presentation. Alkermes is a global biopharmaceutical company specializing in neuroscience, with a portfolio of commercial products for various mental health conditions and a pipeline of candidates for neurological disorders, including narcolepsy.
Alkermes plc (Nasdaq: ALKS) announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at Sleep Europe 2024. ALKS 2680 is an investigational, oral, selective orexin 2 receptor agonist for narcolepsy treatment. The company will share data from NT2 (n=9) and IH (n=8) patient cohorts, where ALKS 2680 was generally well tolerated with improved wakefulness compared to placebo.
Alkermes will also present posters on the study design for ongoing phase 2 studies, Vibrance-1 and Vibrance-2, evaluating ALKS 2680 in narcolepsy type 1 and type 2 patients. The phase 1b study results support further clinical evaluation of ALKS 2680 as a potential treatment for sleep disorders with and without known orexin deficiency.
Alkermes plc (Nasdaq: ALKS) announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference. Management will engage in a fireside chat presentation on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT. A live webcast will be available on the company's website under the Investors tab and archived for 14 days.
Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. Their portfolio includes proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes has additional facilities in Massachusetts and Ohio.
Alkermes plc (Nasdaq: ALKS) has announced the launch of its 7th Annual Alkermes Pathways Research Awards® program, set to begin accepting applications on Sept. 20, 2024. This competitive grant program offers individual grants of up to $100,000 per project to support early-career investigators researching schizophrenia or bipolar disorder. The application period runs through Nov. 30, 2024.
Since its inception in 2018, the program has provided approximately $2.5 million in funding to 25 researchers across the United States. Eligible applicants must be M.D.s, Ph.D.s, or equivalent, within five years of their initial academic appointment or current post-doctoral fellows affiliated with a U.S. medical or research institution. An independent review committee will evaluate applications.
Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company specializing in neuroscience, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat presentation on Wednesday, Sept. 4, 2024, at 2:35 p.m. EDT. Investors can access the live webcast on Alkermes' website under the Investors tab, where it will remain archived for 14 days.
Alkermes focuses on developing innovative medicines for neurological disorders, with a portfolio of commercial products treating conditions such as alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for various neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes maintains a corporate office and research center in Massachusetts and a manufacturing facility in Ohio.
FAQ
What is the current stock price of Alkermes plc (ALKS)?
What is the market cap of Alkermes plc (ALKS)?
What does Alkermes Inc. plc specialize in?
What are some key products of Alkermes?
Where is Alkermes headquartered?
What recent achievements has Alkermes announced?
How did Alkermes perform financially in 2023?
What strategic moves has Alkermes made recently?
What is ALKS 2680?
What initiatives support Alkermes' commitment to mental health?
How can I get more information about Alkermes?
What partnerships or collaborations is Alkermes involved in?
